VOR Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:

Credit Suisse 31st Annual Healthcare Conference

A virtual presentation will be made live starting on Tuesday, November 8, 2022

Stifel 2022 Healthcare Conference

Fireside chat: Wednesday, November 16, 2022 at 10:20 am EST

Location: Lotte New York Palace Hotel, New York, NY

Jefferies London Healthcare Conference

Fireside chat: Thursday, November 17, 2022 at 3:15 pm GMT (10:15 am EST)

Location: The Waldorf Hilton, London, UK

A live webcast and archived replay of the fireside chats along with a replay of the pre-recorded presentation will be available on the investors section of .

About Vor Bio

Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: .

Contact:

Media & Investors

Sarah Spencer



 



EN
01/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vor Biopharma

 PRESS RELEASE

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Sh...

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising environment, the Board of Directors has approved the initiation of a process to explore a range of strategic alternatives aimed at maximizing both near- and long-term shareholder value.   These strategic alternatives could include, among other alternativ...

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch